Mitral and Tricuspid Valve Disease

Interventional treatments of mitral and tricuspid regurgitation have been regarded as technically difficult globally. However, the patient population grows with each passing day. The number of people suffering from mitral regurgitation and tricuspid regurgitation is expected to exceed 22 million by 2025 in China alone, while the patient populations in Europe and the U.S. will reach 14 million and 9.2 million respectively in 2025. In this context, the total potential market value of mitral valve replacement and tricuspid valve replacement in China, Europe, and the U.S. is expected to exceed $4.7 billion in 2030.

Solution

TMVR&TTVR
TMVr&TTVr

Mitral and Tricuspid Valve Disease

Solution

TMVR&TTVR
TMVr&TTVr

Cardiovalve

On December 7th, 2021, Venus Medtech announced the acquisition of Cardiovalve Ltd. The Cardiovalve system independently developed by the company is a transcatheter interventional replacement product for patients suffering from mitral or tricuspid regurgitation. Compared with products of the same kind, its transfemoral approach improves the safety of treatment in significant ways.

Cardiovalve’s treatment of mitral regurgitation has entered clinical trials in Europe and is currently in an early feasibility study in the U.S.. Furthermore, its device for the treatment of tricuspid regurgitation received 'Breakthrough Device Designation' by the FDA in January 2020 and entered an early feasibility study. It is worth mentioning that Cardiovalve is also the first privately held company to receive FDA's early feasibility study (EFS) approval for both TR and MR indications.

For more information, please click:：http://www.cardiovalve.com/

DragonFly™

DragonFly^TM Transcatheter Mitral Valve Repair System (“DF”), independently developed by Valgen Medtech, is the first domestically engineered transfemoral mitral valve clip system approved in China. DragonFly^TM entered the NMPA's Special Review and Approval Procedures for Innovative Medical Devices in March 2021 and received marketing approval on November 29, 2023.

Venus Medtech and Valgen Medtech jointly announced that both parties reached an exclusive strategic marketing cooperation intention in relation to the DragonFly^TM Transcatheter Mitral Valve Repair System of Valgen Medtech on November 22^nd, 2023. Both parties will carry out in-depth commercialization cooperation after the approval for listing of DragonFly^TM. Both parties will join hands and firmly believe that the cooperation will accelerate the development of the diagnosis and treatment of valvular heart diseases in China, and lay a solid foundation for building a comprehensive diagnosis and treatment platform for structural heart diseases in China in the future.